American Century Companies’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

American Century Companies’s Portfolio KDNY Stock Details KDNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-15,060	Closed	-$579K	–	2919
2023 Q2	$579K	Sell	15,060 -90	-0.6%	-$2.31K	﹤0.01%	2153
2023 Q1	$350K	Buy	15,150 +276	+2%	+$6.58K	﹤0.01%	2250
2022 Q4	$390K	Buy	14,874 +4,605	+45%	+$102K	﹤0.01%	2131
2022 Q3	$202K	Buy	+10,269	New	+$206K	﹤0.01%	2227
2019 Q3	–	Sell	-17,487	Closed	-$135K	–	1347
2019 Q2	$135K	Buy	+17,487	New	+$266K	﹤0.01%	1245
2016 Q4	–	Sell	-22,348	Closed	-$1.39M	–	1425
2016 Q3	$1.39M	Sell	22,348 -18	-0.1%	-$1.27K	﹤0.01%	1114
2016 Q2	$1.26M	Buy	+22,366	New	+$1.36M	﹤0.01%	1105

American Century Companies's KDNY Position: Q3 2023 in Review

American Century Companies sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2023, closing a stake of 15,060 shares — an estimated $579K sold.

American Century Companies first reported a position in KDNY in Q2 2016 and held it in 7 quarters. The position peaked at $1.39M in Q3 2016. 2 funds tracked by Wall St. Rank hold KDNY as of Q3 2023.

American Century Companies reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
American Century Companies sold 15,060 Chinook Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $579K.
American Century Companies first reported a position in Chinook Therapeutics, Inc. Common Stock in Q2 2016 and held it in 7 quarters.
American Century Companies's Chinook Therapeutics, Inc. Common Stock position peaked at $1.39M in Q3 2016.
2 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2023.

Based on American Century Companies's 13F filing for Q3 2023, filed 13 Nov 2023.